REAGENTS/MATERIAL: Antibodies—The following antibodies were used in this study: PS1NT was raised against
residues 1–65 of PS1 (paper); antibody Ab14 was raised
against residues 1–25 of PS1 (paper)
(provided by Dr. Sam Gandy, Thomas Jefferson University; Dr. Huaxi Xu, The Burnham Institute); αPS1Loop
was raised against residues 263–407 of PS1; SP716 was raised against residues 62–93 of nicastrin (paper); 3925 recognizes C-terminal 19
amino acids of nicastrin (paper) (provided by Dr. Philip Wong, The Johns Hopkins University School of Medicine); PNT2 was raised against residues
1–26 of PEN-2 (13); O2C2 recognizes C-terminal 20 amino acids of the long isoform of human APH-1a (provided by Drs. Paul Fraser and
Peter St George-Hyslop, the University of Toronto) (paper); anti-BACE-1 was raised against N-terminal 46–163 amino acids (paper) (provided by Dr. Philip Wong);
369 was raised against the cytosolic tail of APP (paper) (provided by Dr. Sam Gandy, Thomas Jefferson University); and 26D6
is a monoclonal antibody raised against Aβ residues 1–12 (Merck) (paper). The following antibodies were purchased from commercial sources:
mouse monoclonal anti-flotillin-2 (29) (BD Transduction );
mouse monoclonal anti-syntaxin-6 (30) (BD Transduction );
mouse monoclonal anti-γ-adaptin (88) (BD Transduction );
mouse monoclonal anti-DCC (G92-13) (BD Transduction );
mouse monoclonal anti-Notch1 (mN1A) (BD Transduction );
mouse monoclonal anti-N-cadherin (32) (BD Transduction );
mouse monoclonal anti-CD8α (OKT8) (ATCC);
mouse monoclonal anti-c-Myc (9E10) (ATCC); anti-caveolin-1 (Santa Cruz) and
rabbit anti-calnexin (Stressgen)